Neoadjuvant Targeting of Myeloid Cell Populations in Combination With Nivolumab in Head & Neck Ca
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Clinical Trials Related to Head and Neck Squamous Cell Carcinoma
Related studies linked through entity extraction aliases.
Study of TL117 in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1/PHASE2
Phase 2 Trial of Maintenance Cemiplimab for Head and Neck Squamous Cell Carcinoma (HNSCC)
- Status
- WITHDRAWN
- Phase
- PHASE2
Neoadjuvant Camrelizumab in Combination With Cisplatin and Nab-paclitaxel in Resectable HNSCC
- Status
- RECRUITING
- Phase
- PHASE2
Neoadjuvant Toripalimab or Toripalimab in Combination With Carboplatin and Nab-paclitaxel in Untreated HNSCC (HNSCC-002)
- Status
- RECRUITING
- Phase
- PHASE2
SPIO-enhanced MRI in Oral Cancer for Sentinel Lymph Node Identification
- Status
- UNKNOWN
- Phase
- NA
Efficacy of Tislelizumab and Spartalizumab Across Multiple Cancer-types in Patients with PD1-high MRNA Expressing Tumors
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
RPTR-168 in Patients With Human Papillomavirus Strain 16 (HPV-16) E6/E7 Positive Tumors and Melanoma
- Status
- TERMINATED
- Phase
- PHASE1
Transdermal Buprenorphine for the Treatment of Radiation-Induced Mucositis Pain in Head and Neck Cancer Patients
- Status
- COMPLETED
- Phase
- PHASE2
Study of Pembrolizumab in the First Line Therapy for R/M HNSCC in China
- Status
- UNKNOWN
- Phase
- N/A
Evaluation of OE-MRI in Patients With H&N Cancer
- Status
- COMPLETED
- Phase
- N/A
A Study of Cemiplimab With Chemotherapy and Immunotherapy in People With Head and Neck Cancer
- Status
- RECRUITING
- Phase
- PHASE1
JAB-3068 Activity in Adult Patients With Advanced Solid Tumors
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
Effectiveness of an Enhanced Tobacco Intervention Protocol Compared to Standard Treatment in Helping Head and Neck and Lung Cancer Patients Starting Treatment to Reduce Cigarette Use
- Status
- COMPLETED
- Phase
- NA
Induction and Maintenance Treatment With PARP Inhibitor and Immunotherapy in HPV-negative HNSCC
- Status
- RECRUITING
- Phase
- PHASE2
Evorpacept (ALX148) in Combination With Pembrolizumab and Chemotherapy in Patients With Advanced Head and Neck Squamous Cell Carcinoma (ASPEN-04)
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Evorpacept (ALX148) in Combination With Pembrolizumab in Patients With Advanced Head and Neck Squamous Cell Carcinoma (ASPEN-03)
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
MIT-001 for Prevention of CCRT-Induced OM in HNSCC Patients
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Enoblituzumab Plus Retifanlimab or Tebotelimab in Head and Neck Cancer
- Status
- TERMINATED
- Phase
- PHASE2
Tazemetostat and Pembrolizumab in Patients With Pembrolizumab- or Nivolumab-Resistant, Recurrent or Metastatic Head and Neck Squamous-Cell Carcinoma
- Status
- TERMINATED
- Phase
- PHASE1